Supernus Pharmaceuticals, Inc. beat EPS estimates 75% of the time across 16 reported quarters (12 beats, 4 misses), averaging +28.9% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $0.30 | $0.39 | +30.0% | Beat | |
| Q1 FY26 | not reported | $0.45 | not reported | not reported | |
| Q4 FY25 | not reported | $0.75 | not reported | not reported | Q4 FY25 call |
| Q3 FY25 | $0.33 | $0.46 | +39.4% | Beat | |
| Q2 FY25 | $0.34 | $0.78 | +129.4% | Beat | |
| Q1 FY25 | $0.26 | $0.28 | +7.7% | Beat | |
| Q4 FY24 | $0.40 | $0.61 | +52.5% | Beat | |
| Q3 FY24 | not reported | $0.95 | not reported | not reported | |
| Q2 FY24 | $0.26 | $0.36 | +38.5% | Beat | |
| Q1 FY24 | $0.27 | $0.00 | -100.0% | Miss | |
| Q4 FY23 | not reported | $0.02 | not reported | not reported | |
| Q3 FY23 | not reported | $-0.29 | not reported | not reported |
Back to SUPN overview · SUPN holders · SUPN KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.